# Inotuzumab Ozogamicin in the Treatment of MRD+ After HSCT of ALL

> **NCT05940961** · PHASE2 · RECRUITING · sponsor: **Sheng-Li Xue, MD** · enrollment: 42 (estimated)

## Conditions studied

- ALL
- MRD-positive
- Hematopoietic Stem Cell Transplantation

## Interventions

- **DRUG:** Inotuzumab Ozogamicin

## Key facts

- **NCT ID:** NCT05940961
- **Lead sponsor:** Sheng-Li Xue, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-08-01
- **Primary completion:** 2026-08-01
- **Final completion:** 2026-08-01
- **Target enrollment:** 42 (ESTIMATED)
- **Last updated:** 2025-11-21

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05940961

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05940961, "Inotuzumab Ozogamicin in the Treatment of MRD+ After HSCT of ALL". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT05940961. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*